Insider Buying: Hemab Therapeutics (NASDAQ:COAG) Director Buys $1,673,242.80 in Stock

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Director Ra Capital Management, L.P. purchased 68,018 shares of Hemab Therapeutics stock in a transaction on Wednesday, May 6th. The stock was bought at an average cost of $24.60 per share, with a total value of $1,673,242.80. Following the completion of the acquisition, the director owned 6,314,525 shares in the company, valued at approximately $155,337,315. This trade represents a 1.09% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, May 5th, Ra Capital Management, L.P. purchased 97,411 shares of Hemab Therapeutics stock. The stock was bought at an average cost of $24.63 per share, with a total value of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock. The stock was bought at an average cost of $18.00 per share, with a total value of $48,150,000.00.

Hemab Therapeutics Price Performance

Shares of Hemab Therapeutics stock opened at $25.12 on Friday. Hemab Therapeutics Holdings, Inc. has a fifty-two week low of $23.48 and a fifty-two week high of $36.61.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a report on Saturday.